Cell-specific delivery of biologicals: Problems, pitfalls and possibilities of antifibrotic compounds in the liver

Drug Discovery Today

Volumn 18, Issue 23-24, 2013, Pages 1237-1242

  Poelstra, Klaas ^a   Beljaars, Leonie ^a   Melgert, Barbro N ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN; ANTIFIBROTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; DENDRIMER; DEXAMETHASONE; DOXORUBICIN; DRUG CARRIER; GAMMA INTERFERON; LIPOSOME; MANNOSE 6 PHOSPHATE; OLIGONUCLEOTIDE; PEGASUS; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RETINOL; SCATTER FACTOR; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

CELL SPECIFICITY; CELL TYPE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FIBROBLAST; HUMAN; IN VITRO STUDY; LIVER FIBROSIS; NONHUMAN; REVIEW; STELLATE CELL; TARGET CELL; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG DESIGN; LIVER CIRRHOSIS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FIBROBLASTS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS;

EID: 84889082081     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.013     Document Type: Review

References (75)

1. J. Kling Fresh from the biotech pipeline - 2011 Nat. Biotechnol. 30 2012 128 131
2. H. Schooltink, and S. Rose-John Cytokines as therapeutic drugs J. Interferon Cytokine Res. 22 2002 505 516
3. V. Tayal, and B.S. Kalra Cytokines and anti-cytokines as therapeutics - an update Eur. J. Pharmacol. 579 2008 1 12
4. H. Tilg How to modulate inflammatory cytokines in liver diseases Liver Int. 26 2006 1029 1039
5. T.B. Kelleher, and N. Afdhal Maintenance therapy for chronic hepatitis C Curr. Gastroenterol. Rep. 7 2005 50 53
6. European Association of the Study of the Liver European association of the study of the liver hepatitis C virus clinical practice guidelines Liver Int. 32 Suppl 1 2012 2 8
7. G. Pasut, and F.M. Veronese State of the art in PEGylation: the great versatility achieved after forty years of research J. Control Release 161 2012 461 472
8. J. Banchereau From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines Nat. Immunol. 13 2012 925 931
9. A. Mantovani The chemokine system in diverse forms of macrophage activation and polarization Trends Immunol. 25 2004 677 686
10. V. Barbarin Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles Am. J. Physiol. Lung Cell Mol. Physiol. 288 2005 L841 L848
11. J.C. Burnett, and J.J. Rossi RNA-based therapeutics: current progress and future prospects Chem. Biol. 19 2012 60 71
12. C. Alabi Attacking the genome: emerging siRNA nanocarriers from concept to clinic Curr. Opin. Pharmacol. 12 2012 427 433
13. P. Kesharwani A review of nanocarriers for the delivery of small interfering RNA Biomaterials 33 2012 7138 7150
14. M. Rumi Comparative trials of peginterferon alpha2a and peginterferon alpha2b for chronic hepatitis C J. Viral Hepat. 19 Suppl 1 2012 37 41
15. R. Bruno Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles J. Viral Hepat. 19 Suppl 1 2012 33 36
16. P.J. Pockros Drugs in development for chronic hepatitis C: a promising future Expert Opin. Biol. Ther. 11 2011 1611 1622
17. C.A. Stedman Current prospects for interferon-free treatment of hepatitis C in 2012 J. Gastroenterol. Hepatol. 28 2013 38 45
18. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control Release 132 2008 171 183
19. M. Slingerland Liposomal drug formulations in cancer therapy: 15 years along the road Drug Discov. Today 17 2012 160 166
20. F. Li Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis J. Control Release 131 2008 77 82
21. J. Fang The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
22. E.A. Azzopardi The enhanced permeability retention effect: a new paradigm for drug targeting in infection J. Antimicrob. Chemother. 68 2013 257 274
23. G. Bendas The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes Biochim. Biophys. Acta 1609 2003 63 70
24. T. Shimizu Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response Biol. Pharm. Bull. 35 2012 1336 1342
25. T. Ishida PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner J. Control Release 122 2007 349 355
26. D.C. Rockey Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma Hepatology 16 1992 776 784
27. D.M. Mosser, and J.P. Edwards Exploring the full spectrum of macrophage activation Nat. Rev. Immunol. 8 2008 958 969
28. W.I. Jeong Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice Hepatology 53 2011 1342 1351
29. Y.L. Han Reciprocal interaction between macrophages and T cells stimulates IFN-gamma and MCP-1 production in ang II-induced cardiac inflammation and fibrosis PLoS One 7 2012 e35506
30. I. Locatelli NF-kB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses Clin. Sci. (Lond.) 124 2013 279 287
31. A.M. Gressner, and R. Weiskirchen Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets J. Cell Mol. Med. 10 2006 76 99
32. C. Yao Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion Nat. Med. 15 2009 633 640
33. M.J. Ruwart The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat Hepatology 10 1989 801 806
34. J. Bosch Vascular deterioration in cirrhosis: the big picture J. Clin. Gastroenterol. 41 Suppl 3 2007 S247 S253
35. M. Pinzani Fibrosis in chronic liver diseases: diagnosis and management J. Hepatol. 42 Suppl 1 2005 S22 S36
36. D. Schuppan, and M. Pinzani Anti-fibrotic therapy: lost in translation? J. Hepatol. 56 Suppl 1 2012 S66 S74
37. J.A. Fallowfield, and J.P. Iredale Targeted treatments for cirrhosis Expert Opin. Ther. Targets 8 2004 423 435
38. E.L. Ellis, and D.A. Mann Clinical evidence for the regression of liver fibrosis J. Hepatol. 56 2012 1171 1180
39. P. Kocabayoglu, and S.L. Friedman Cellular basis of hepatic fibrosis and its role in inflammation and cancer Front. Biosci. (Schol. Ed.) 5 2013 217 230
40. A.A. Nanji Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat Gastroenterology 112 1997 943 951
41. A. Mallat Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors J. Biol. Chem. 273 1998 27300 27305
42. P.J. Pockros Oral IDN-6556: an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C Hepatology 46 2007 324 329
43. J.P. Iredale Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors J. Clin. Invest. 102 1998 538 549
44. J.S. Troeger Deactivation of hepatic stellate cells during liver fibrosis resolution in mice Gastroenterology 143 2012 e22 1073-83
45. K. Breitkopf Anti-TGF-beta strategies for the treatment of chronic liver disease Alcohol Clin. Exp. Res. 29 11 Suppl 2005 121S 131S
46. B.R. Achyut, and L. Yang Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment Gastroenterology 141 2011 1167 1178
47. J.M. Reichert, and E. Dhimolea The future of antibodies as cancer drugs Drug Discov. Today 17 2012 954 963
48. N.W. van de Donk, and E. Dhimolea Brentuximab vedotin MAbs 4 2012 458 465
49. K. Poelstra Drug targeting to the diseased liver J. Control Release 161 2012 188 197
50. K. Poelstra, and D. Schuppan Targeted therapy of liver fibrosis/cirrhosis and its complications J. Hepatol. 55 2011 726 728
51. L. Beljaars Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells Hepatology 29 1999 1486 1493
52. L. Beljaars The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue Biochem. Pharmacol. 66 2003 1307 1317
53. R. Bansal Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice Hepatology 54 2011 586 596
54. S. Klein HSC-specific inhibition of rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects J. Hepatol. 57 2012 1220 1227
55. M. Moreno Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats Hepatology 51 2010 942 952
56. M.H. Schoemaker PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells Mol. Pharm. 5 2008 399 406
57. J.E. Adrian Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems J. Hepatol. 44 2006 560 567
58. N. Yang Targeted TFO delivery to hepatic stellate cells J. Control Release 155 2011 326 330
59. A. Douglass Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury J. Hepatol. 49 2008 88 98
60. Y. Sato Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone Nat. Biotechnol. 26 2008 431 442
61. R. Bansal A novel interferon gamma peptidomimetic inhibits early and progressive liver fibrogenesis in vivo Hepatology 54 suppl 4 2011 732A
62. S.S. Glaser Cholangiocyte proliferation and liver fibrosis Expert Rev. Mol. Med. 11 2009 e7
63. G. Syal Advances in cholangiocyte immunobiology Am. J. Physiol. Gastrointest. Liver Physiol. 303 2012 G1077 G1086
64. E. Patsenker Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression Gastroenterology 135 2008 660 670
65. T.A. Wynn, and T.R. Ramalingam Mechanisms of fibrosis: therapeutic translation for fibrotic disease Nat. Med. 18 2012 1028 1040
66. J.S. Duffield Selective depletion of macrophages reveals distinct: opposing roles during liver injury and repair J. Clin. Invest. 115 2005 56 65
67. B.N. Melgert Targeting dexamethasone to kupffer cells: effects on liver inflammation and fibrosis in rats Hepatology 34 4 Pt 1 2001 719 728
68. C. Albrecht Targeting naproxen coupled to human serum albumin to nonparenchymal cells reduces endotoxin-induced mortality in rats with biliary cirrhosis Hepatology 26 1997 1553 1559
69. X. Zhao Targeted drug delivery via folate receptors Expert Opin. Drug Deliv. 5 2008 309 319
70. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701
71. S.M. Moghimi Particulate systems for targeting of macrophages: Basic and therapeutic concepts J. Innate Immun. 4 2012 509 528
72. S.I. Kim Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes J. Hepatol. 50 2009 479 488
73. L. Fiume, and G. Di Stefano Lactosaminated human albumin: a hepatotropic carrier of drugs Eur. J. Pharm. Sci. 40 2010 253 262
74. D. Descamps, and K. Benihoud Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction Curr. Gene Ther. 9 2009 115 127
75. Y. Hayashi Potential use of lactosylated dendrimer (G3)/alpha- cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy Mol. Pharm. 9 2012 1645 1653